May 4th, 2021 - Monoclonal antibodies (mAbs) encoded by IGHV3-53 (VH3-53) targeting the spike receptor-binding domain (RBD) have been isolated from different COVID-19 patients. However, the existence and prevalence of shared VH3-53-encoded antibodies in the antibody repertoires is not clear. Using antibody repertoire sequencing, we found that the usage of VH3-53 increased after SARS-CoV-2 infection. A highly s...

May 3rd, 2021 - This study aims to compare the RBD SARS-CoV-2-specific antibody titers in human milk between mothers with a confirmed COVID-19 PCR test and mothers with viral symptoms suggestive of COVID-19. The area under the curve (AUC) for RBD SARS-CoV-2-specific SIgA/IgA, SIgM/IgM, IgG, and free secretory components (fSC) in milk samples from eight mothers with a confirmed COVID-19 PCR, eight mothers with ...

May 3rd, 2021 - (Reuters) - Some COVID-19 survivors infected early in the pandemic still have detectable antibodies against the virus a year later, according to a new study. U.S. doctors collected blood samples from 250 patients, including 58 who had been hospitalized for COVID-19 and 192 who had not required hospitalization. Six-to-10 months after diagnosis, all of the former inpatients and 95% of the outpati...

May 3rd, 2021 - (Reuters) - An experimental monoclonal antibody treatment for COVID-19 being developed by Eli Lilly and Co and AbCellera Biologics Inc can "potently" neutralize numerous coronavirus variants, including those first identified in the UK, Brazil, South Africa, California and New York, scientists have found in test tube experiments. The antibody - known as LY-CoV1404 or LY3853113 - works by attachi...

May 3rd, 2021 - The characterization of the adaptive immune response to COVID-19 vaccination in individuals who recovered from SARS-CoV-2 infection may define current and future clinical practice. To determine the effect of two doses BNT162b2 mRNA COVID-19 vaccination schedule in individuals who recovered from COVID-19 (COVID-19 recovered) compared to naïve subjects, we evaluated SARS-CoV-2 Spike-specific T an...

May 2nd, 2021 - LONDON (Reuters) - A single dose of Pfizer's coronavirus vaccine may not generate a sufficient immune response to protect against dominant new variants, except in people who have already been infected with COVID-19, according to a UK study published on Friday. The Imperial College-led study, which looked at immune responses among healthcare workers in Britain after their first dose of the Pfize...

May 2nd, 2021 - In England, the reopening of universities in September 2020 coincided with a rapid increase in SARS-CoV-2 infection rates in university aged young adults. This study aimed to estimate SARS-CoV-2 antibody prevalence in students attending universities that had experienced a COVID-19 outbreak after reopening for the autumn term in September 2020. A cross-sectional serosurvey was conducted during 0...

May 2nd, 2021 - MOSCOW (Reuters) - Russia has produced the world's first batch - 17,000 doses - of COVID-19 vaccines for animals, its agricultural regulator said on Friday. Russia registered Carnivac-Cov in March after tests showed it generated antibodies against COVID-19 in dogs, cats, foxes and mink. The first batch will be supplied to several regions of Russia, the regulator Rosselkhoznadzor said in a state...

May 1st, 2021 - Antinuclear antibodies in COVID 19.|2021|Muratori P,Lenzi M,Muratori L,Granito A,|

May 1st, 2021 - PCR is the current standard test for the diagnosis of SARS-CoV-2 infection. However, due to its limitations, serological testing is considered an alternative method for detecting SARS-CoV-2 exposure. In this study, we measured the level of SARS-CoV-2 IgM and IgG antibodies of male professional football players and compared the results with the standard PCR test to investigate the association be...

May 1st, 2021 - Timing of detection of IgG, IgA and IgM antibodies against SARS-CoV-2, and their use to support the diagnosis are of increasing interest. We used the Gold Standard Diagnostics ELISA to evaluate the kinetics of SARS-CoV-2 IgG, IgA and IgM antibodies in sera of 82 hospitalized patients with PCR-confirmed COVID-19. Serum samples were collected 1-59 days post onset of symptoms (PoS) and we examined...

May 1st, 2021 - Investigating the dynamic characteristics of serologic antibodies against SARS-CoV-2 is of significance. Here, the dynamic changes and prevalence of IgM and IgG antibodies against SARS-CoV-2 from symptoms onset to 210 days were described. Antibodies were detected by a chemiluminescence immunoassay. For all patients, the average titers and positive rates of IgG/IgM within 30 days from symptoms o...

May 1st, 2021 - Longevity of anti-SARS-CoV-2 antibody level and duration of immunity are current topics of major scientific interest. Antibody kinetics during the acute phase are well-studied, whereas long-term kinetics are yet to be determined and available studies are controversial. Here, results of longitudinal analysis of serological responses to SARS-CoV-2 infection after convalescent and its association ...

May 1st, 2021 - H5-subtype highly pathogenic (HP) avian influenza viruses (AIVs) cause high mortality in domestic birds and sporadic infections in humans with a frequently fatal outcome, while H5N1 viruses have pandemic potential. Due to veterinary and public health significance, these HPAIVs, as well as low pathogenicity (LP) H5-subtype AIVs having a propensity to mutate into HP viruses, are under epidemiolog...

May 1st, 2021 - Oncology is the frontline of drug development. The current pharmaceutical pipeline is disproportional focused on oncology, where about 1/3 of all phases of development is in this therapeutic area. The emphasis brings about substantial breakthrough and has made positive impact on the quality of life. However, oncology remains a threat to human existence, and more will be needed. To facilitate th...

Apr 30th, 2021 - ABSTRACTNeutralizing antibodies to SARS-CoV-2 have been shown to correlate with protection in animals and humans, disease severity, survival, and vaccine efficacy. With the ongoing large-scale vaccination in different countries and continuous surge of new variants of global concerns, a convenient, cost-effective and high-throughput neutralization test is urgently needed. Conventional SARS-CoV-2...

Apr 30th, 2021 - Evidence is currently insufficient to know whether SARS-CoV-2 antibodies (Abs) protect from future infection and how long immunity will last. The kinetics of the immune response to SARS-CoV-2 infection and role of serology in estimating individual protective immunity is yet to be established. We evaluated diagnostic performances of three serological assays - Abbott Architect CMIA IgG, bioMerieu...

Apr 30th, 2021 - Healthcare workers (HCWs) are at the front line of the ongoing coronavirus pandemic. Comprehensively evaluating SARS-CoV-2 seroprevalence among HCWs in a large healthcare system could help identify the impact that epidemiological factors and presence of symptoms have on immune response to the infection over time. To determine the seroprevalence of SARS-CoV-2 specific antibodies among healthcare...

Apr 30th, 2021 - Determining the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in health care workers (HCWs) based on risk of exposure to COVID-19 patients. SARS-CoV-2 seroprevalence cross-sectional study in risk-stratified HCWs randomly selected from 3 main district hospitals in Oman. 1,078 HCWs included with an overall SARS-CoV-2 seroprevalence of 21%. The seropositivity in lo...

Apr 30th, 2021 - SARS coronavirus 1 (SARS-CoV-1) causes a respiratory infection that can lead to acute respiratory distress characterized by inflammation and high levels of cytokines in the lung tissue. In this study we constructed a herpes simplex virus 1 replication-defective mutant vector expressing SARS-CoV-1 spike protein as a potential vaccine vector and to probe the effects of spike protein on host cells...